Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER) reported second quarter 2026 results and clinical progress for SER-252, its POZ-based apomorphine candidate for Parkinson’s disease. Enrollment and dosing of all eight patients in Cohort 1 of the Phase 1b registrational study were completed in July 2026, ahead of prior guidance, with a blinded safety review and dose‑escalation decision to follow. Top‑line data from the single‑ascending‑dose arm are targeted for the first half of 2027.
Serina entered a development partnership with Gannet BioChem for SER‑252 process development, scale‑up and manufacturing, and appointed Farrell Simon, Pharm.D., to its Board and key committees. For Q2 2026, operating expenses rose to $6.8 million from $5.7 million, and net loss attributable to common shareholders was $8.9 million, or $(0.55) per share, versus $6.6 million, or $(0.66) per share, in 2025. Cash and cash equivalents increased to $23.0 million at June 30, 2026, up from $3.1 million at year‑end 2025, driven primarily by $31.3 million of financing inflows in the first half of 2026.
Positive
- Cohort 1 enrollment/dosing completed in July 2026, ahead prior Q3 2026 guidance
- Top-line Phase 1b data from SER-252 single-ascending-dose arm targeted 1H 2027
- Partnership with Gannet BioChem to support SER-252 process development and manufacturing
- Cash and equivalents $23.0M at June 30, 2026 vs. $3.1M at December 31, 2025
- Total stockholders’ equity improved to $18.7M at June 30, 2026 from $(0.04)M at year-end 2025
- Other income, net Q2 2026 of $0.4M vs. $0.9M expense in Q2 2025
Negative
- Total operating expenses Q2 2026 $6.8M vs. $5.7M in Q2 2025
- Net loss attributable to common shareholders Q2 2026 $8.9M vs. $6.6M in Q2 2025
- Net cash used in operating activities $11.3M for six months ended June 30, 2026 vs. $8.1M in 2025
- Grant revenues $0 in Q2 and first half 2026 vs. $0.1M in comparable 2025 periods
- Interest expense Q2 2026 $0.2M vs. near-zero $0.01M in Q2 2025
- Reliance on financing cash flows $31.3M provided in first half 2026 to support operations
News Explained
At
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 earnings report | Negative | -4.7% | Reported losses and operating expenses while maintaining clinical development and financing updates |
| Mar 25 | FY earnings report | Negative | -13.9% | Reported annual losses and financing activity despite FDA clearance and Phase 1b initiation |
| Nov 13 | Q3 earnings report | Negative | -2.5% | Disclosed clinical hold, financing arrangements, and continuing operating losses |
| Aug 11 | Q2 earnings report | Negative | +7.1% | Reported net loss and higher expenses alongside increased revenue and financing |
| May 08 | Q1 earnings report | Positive | -2.0% | Reported improved loss and equity financing while preparing the SER-252 Phase 1b trial |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific history showed a negative average reaction of -3.19% across five prior earnings events, with three of five reactions aligned with negative earnings-related developments.
Key Terms
pharmacokinetics medical
single-ascending-dose medical
double-blind medical
placebo-controlled medical
poly(2-oxazoline) technical
convertible note financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -
- Top-line data from the single-ascending-dose arm targeted for the first half of 2027 -
- Appointment of Farrell Simon, Pharm.D., to the Board of Directors -
HUNTSVILLE, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the second quarter ended June 30, 2026, along with key business updates.
“We continued on our strategic plan, completing enrollment and dosing in Cohort 1 of the SER-252 registrational study ahead of our prior guidance,” said Steve Ledger, Chief Executive Officer of Serina. “Completion of Cohort 1 progresses the program to its next protocol-defined safety review and dose-escalation decision as we expect top-line data from the single-ascending-dose arm in the first half of 2027. We also strengthened the capabilities supporting SER-252 and the broader POZ Platform through our development partnership with Gannet BioChem and the appointment of Farrell Simon to our Board. Our near-term priority remains disciplined clinical execution and generating the data needed to evaluate whether SER-252 can deliver a differentiated product profile for patients with advanced Parkinson’s disease, where a high unmet need for more tolerable therapies continues to exist.”
Recent Business Highlights
- SER-252 Phase 1b Registrational Clinical Study: Following completion of sentinel dosing and the independent Safety Monitoring Committee’s recommendation to continue dosing, Serina completed enrollment and dosing of all eight patients in Cohort 1 in July 2026. The milestone was achieved ahead of the Company’s previously disclosed guidance of the end of the third quarter of 2026. The study protocol provides for a blinded review of Cohort 1 safety and tolerability observations by the independent Safety Monitoring Committee to inform the next dose-escalation decision. Top-line data from the single-ascending-dose arm remain targeted for the first half of 2027.
- Development Partnership with Gannet BioChem: In June 2026, Serina entered into a development partnership with Gannet BioChem to support process development, scale-up and manufacturing activities for SER-252. The collaboration expands the technical capabilities supporting the continued advancement of Serina’s lead clinical program and broader pipeline.
- Board Appointment: In July 2026, Serina appointed Farrell Simon, Pharm.D., to its Board of Directors and its Audit and Compensation Committees. Dr. Simon brings experience across commercial strategy, operations, business development and investor engagement, including his current role as Chief Commercial Officer of Trevi Therapeutics and prior senior leadership roles at Pfizer.
Second Quarter Operating Results
Operating expenses: Operating expenses for the three months ended June 30, 2026 and 2025 were
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative Expenses
General and Administrative Expenses: General and administrative expenses were
Other Income, Net: Other income was
Net (Loss) Income: The net loss attributable to Serina common shareholders for the three months ended June 30, 2026 was
Liquidity Information
Cash and cash equivalents totaled
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
About the POZ Platform™
Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions.
SER-252 Registrational Study Design Overview
The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The registrational study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.
For more information, please visit https://serinatx.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. The facts and assumptions underlying these statements may change, and undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made. Any statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,” “intends,” “anticipates,” "targeting," “expects,” or “estimates”) should be considered to be forward-looking statement, including statements about the potential of Serina’s POZ polymer technology, Serina’s estimates regarding future revenue, expenses, capital requirements and need for additional financing, and Serina’s planned clinical programs, including planned clinical trials. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory holds, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina’s ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and, except as required by law, Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
SERINA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(Unaudited)
| June 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 23,024 | $ | 3,056 | ||||
| Prepaid expenses and other current assets | 2,006 | 3,024 | ||||||
| Total current assets | 25,030 | 6,080 | ||||||
| Property and equipment, net | 482 | 465 | ||||||
| Right of use assets - operating leases | 277 | 377 | ||||||
| Other long-term prepaid assets | 25 | 29 | ||||||
| TOTAL ASSETS | $ | 25,814 | $ | 6,951 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,858 | $ | 1,931 | ||||
| Accrued expenses | 1,359 | 1,207 | ||||||
| Warrant liability | — | 88 | ||||||
| Other current liabilities | 545 | 337 | ||||||
| Total current liabilities | 3,762 | 3,563 | ||||||
| Warrant liability, non-current | 113 | 283 | ||||||
| Convertible Note, net | 3,087 | 2,946 | ||||||
| Operating lease liabilities, net of current portion | 122 | 196 | ||||||
| Total liabilities | 7,084 | 6,988 | ||||||
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | 18,730 | (37 | ) | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ | 25,814 | $ | 6,951 | ||||
SERINA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| REVENUES | ||||||||||||||||
| Grant revenues | $ | — | $ | 130 | $ | — | $ | 130 | ||||||||
| Total revenues | — | 130 | — | 130 | ||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| Research and development | 3,816 | 3,152 | 7,015 | 6,103 | ||||||||||||
| General and administrative | 2,968 | 2,543 | 6,049 | 5,450 | ||||||||||||
| Total operating expenses | 6,784 | 5,695 | 13,064 | 11,553 | ||||||||||||
| Loss from operations | (6,784 | ) | (5,565 | ) | (13,064 | ) | (11,423 | ) | ||||||||
| OTHER INCOME (EXPENSE), NET | ||||||||||||||||
| Interest expense | (203 | ) | (9 | ) | (392 | ) | (9 | ) | ||||||||
| Change in fair value of warrants | 50 | (956 | ) | 154 | 33 | |||||||||||
| Change in fair value of tranche liability | 347 | — | 1,377 | — | ||||||||||||
| Loss on extinguishment of financial commitment assets and contingent warrants, net | — | — | (1,616 | ) | — | |||||||||||
| Other income, net | 234 | 68 | 287 | 115 | ||||||||||||
| Total other income (expense), net | 428 | (897 | ) | (190 | ) | 139 | ||||||||||
| NET LOSS | $ | (6,356 | ) | $ | (6,462 | ) | $ | (13,254 | ) | $ | (11,284 | ) | ||||
| NET LOSS ATTRIBUTABLE TO SERINA COMMON STOCKHOLDERS | $ | (8,932 | ) | $ | (6,565 | ) | $ | (15,867 | ) | $ | (11,378 | ) | ||||
| NET LOSS ATTRIBUTABLE TO SERINA COMMON SHAREHOLDER, BASIC AND DILUTED | $ | (0.55 | ) | $ | (0.66 | ) | $ | (1.11 | ) | $ | (1.15 | ) | ||||
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC AND DILUTED | 16,385 | 10,004 | 14,232 | 9,883 | ||||||||||||
SERINA THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
| Six months ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities | $ | (11,252 | ) | $ | (8,072 | ) | ||
| Net cash used in investing activities | (53 | ) | (46 | ) | ||||
| Net cash provided by financing activities | 31,259 | 10,487 | ||||||
| Effect of foreign currency on cash and cash equivalents | 14 | — | ||||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 19,968 | 2,369 | ||||||
| CASH AND CASH EQUIVALENTS: | ||||||||
| At beginning of the period | 3,056 | 3,672 | ||||||
| At end of the period | $ | 23,024 | $ | 6,041 | ||||
